Darzalex Faspro-Based Quadruplet Regimen Approved in the U.S. for Newly Diagnosed Patients With Multiple Myeloma Who are Transplant Ineligible
January 29, 2026
January 29, 2026
RARITAN, New Jersey, Jan. 29 -- Johnson and Johnson Innovative Medicine issued the following news release:
* * *
DARZALEX FASPRO(R)-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible
Quadruplet regimen demonstrated significantly deeper and more durable responses, higher MRD negativity and improved progression-free survival versus a standard of care
Approval marks the t . . .
* * *
DARZALEX FASPRO(R)-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible
Quadruplet regimen demonstrated significantly deeper and more durable responses, higher MRD negativity and improved progression-free survival versus a standard of care
Approval marks the t . . .